IOIBD technical review on endoscopic indices for Crohn's disease clinical trials

Vuitton, Lucine; Marteau, Philippe; Sandborn, William J.; Levesque, Barrett G.; Feagan, Brian G.; Vermeire, Séverine; Danese, Silvio; D’Haens, Geert R.; Löwenberg, Mark; Khanna, Reena; Fiorino, Gionata; Travis, Simon; Mary, Jean‐Yves; Peyrin–Biroulet, Laurent

doi:10.1136/gutjnl-2015-309903

Cited by 155 publications

(101 citation statements)

References 51 publications

Supporting

Mentioning

101

Contrasting

Order By: Relevance

“…Endoscopic mucosal healing was defi ned as the absence of ulcers and/or erosions ( 10,15 ). Given the potential variability in endoscopic scoring ( 16 ), endoscopic categorization of mucosal…”

Section: Discussionmentioning

confidence: 99%

The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium

Dulai

Singh

Jiang

et al. 2016

American Journal of Gastroenterology

269

235

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium

Dulai

Singh

Jiang

et al. 2016

American Journal of Gastroenterology

269

235

View full text Add to dashboard Cite

show abstract

“…(16) Validated endoscopic scoring systems include the CD Endoscopic Index of Severity (CDEIS) and the Simple Endoscopic Score for CD (SES-CD). (4, 43, 44) The CDEIS consists of recording 9 descriptors across 5 segments including the ileum. The weaknesses of the CDEIS include its complex requirement of data recording, possible underestimation of the severity of disease when only one out of five segments is involved, and the absence of validated score thresholds associated with specific prognostic outcomes.…”

Section: Non-radiologic Criteria and End-pointsmentioning

confidence: 99%

Computed Tomography and Magnetic Resonance Enterography in Crohnʼs Disease

Deepak

Fletcher

Fidler

2016

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

Early recognition of Crohn’s disease (CD) with initiation of disease modifying therapy has emerged as a prominent inflammatory bowel disease (IBD) management strategy. . Clinical practice and trials have often focused on patient symptoms, and more recently, serologic tests, stool inflammatory markers, and/or endoscopic inflammatory features for study entry criteria, treatment targets, disease activity monitoring, and to assess therapeutic response Unfortunately, patient symptoms do not correlate well with biologic disease activity, and endoscopy potentially misses or underestimates disease extent and severity in small bowel CD. Computed tomography enterography (CTE) and magnetic resonance enterography (MRE) are potential tools to identify and quantify transmural structural damage and disease activity in the small bowel. In this review, we discuss the role of CTE and MRE in disease management algorithms in clinical practice. We also compare the currently developed MRE based scoring systems, their strengths and pitfalls, as well as the role for MRE in clinical trials for CD.

show abstract

“…These results highlight the importance of determining a standardized definition of mucosal healing, which may also be histological. Advantages and disadvantages of each score are available in (Table 1) [8,10,[13][14][15][16][17]. …”

Section: Endoscopic Mucosal Healingmentioning

confidence: 99%

“…Regarding CD, a panel of experts recently proposed the threshold for endoscopic remission to be defined as a SES-CD score (Simplified Endoscopic Score for Crohn's Disease) of between 0 and 2 [8]. In current practice, Rutgeert's score is used to evaluate the endoscopic postoperative recurrence commonly defined as a score ≥ i2 (5 or more aphtous ulcers at the site of anastomosis).…”

Section: Endoscopic Mucosal Healingmentioning

confidence: 99%

Assessment of Mucosal Healing in Inflammatory Bowel Disease

Auzoux¹,

Boschetti²,

Lahlou³

et al. 2017

J Clin Gastroenterol Hepatol

View full text Add to dashboard Cite

In recent decades, the advent of biological therapy has changed the treatment of inflammatory bowel disease (IBD) and has opened new therapeutic endpoints such as mucosal healing (MH). MH incorporated with clinical remission presents a new concept: deep remission, which correlates with a decrease in hospitalization and surgery and improvement in the patient's quality of life. Several techniques can be used to assess mucosal healing such as endoscopy which remains the gold standard. But considerable variations may exist in the interpretation of the definition of mucosal healing which may also be histological or evaluated by radiological or biological methods. Thus, it is important to study mucosal inflammation by endoscopic scores and by new, more sensitive techniques such as videocapsule endoscopy (VCE), magnetic resonance enterography (MRE), chromoendoscopy and confocal laser endomicroscopy (CLE). Biomarkers, such as fecal calprotectin (FC) were also studied in the evaluation of MH and showed positive results. These methods are currently the subject of validation studies.

show abstract

IOIBD technical review on endoscopic indices for Crohn's disease clinical trials

Cited by 155 publications

References 51 publications

The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium

The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium

Computed Tomography and Magnetic Resonance Enterography in Crohnʼs Disease

Assessment of Mucosal Healing in Inflammatory Bowel Disease

Contact Info

Product

Resources

About